U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07409948) titled 'Multicomponent Care for Aromatase Inhibitor-Related Musculoskeletal Symptoms' on Feb. 02.
Brief Summary: Breast cancer patients who receive endocrine therapy particularly aromatase inhibitors often experience aromatase inhibitors associated symptoms (AIMSS) such as joint and muscle pain along with stiffness and fatigue that can disrupt with daily activities and lead some patients to stop treatment early. A structured intervention program named AIMSS-CARE (Aromatase Inhibitor-associated Musculoskeletal Symptoms-Comprehensive Adapted Rehabilitation Evaluation) developed in China that combines exercise, education, symptom monitoring, a...